Navigation Links
Hormonal Changes and Depression: What is the Connection?
Date:11/13/2007

Society for Women's Health Research Report and Media Briefing Explore Impact of Hormonal Transitions on Women's Mood Disorders

WASHINGTON, Nov. 13 /PRNewswire-USNewswire/ -- Women are more susceptible to mood disorders and depression during hormonal transitions, such as pregnancy, postpartum and perimenopause, according to a new report by the Society for Women's Health Research, a Washington, D.C.-based advocacy organization, released at a media briefing held at the Palace Hotel in New York City today.

The report summarizes a June 2007 thought leaders' roundtable of eight national experts convened by the Society and the National Institute of Mental Health to discuss current efforts to understand the effects of hormonal transitions on mood disorders in women and to make recommendations for future research.

"Women need to be critically aware of changes in their moods during key life cycle events," said Sherry Marts, Ph.D. and vice president of scientific affairs for the Society. "The roundtable kicked off a much needed discussion about the relationship between hormonal transitions and mood disorders. Through the media briefing and the publishing of this report we hope to generate a broader understanding of how we can use this knowledge to improve health outcomes for women."

Leading women's health experts and roundtable participants Peter Schmidt, M.D., an investigator in the National Institute of Mental Health's Reproductive Endocrine Studies Unit, and Zachary Stowe, M.D., an associate professor of psychiatry and behavioral sciences and gynecology and obstetrics at Emory University School of Medicine in Atlanta, Ga., reconvened at the briefing to discuss their research findings detailed in the report. They were joined on the briefing panel by Meir Steiner, M.D., Ph.D., a professor of psychiatry and behavioral neurosciences, obstetrics and gynecology at McMaster University in Hamilton, Ontario, Canada. Marts moderated the session.

The panelists noted that while it is natural for women to experience changes in their feelings and mood during life cycle transitions, hormonal fluctuations in some women may trigger mild to severe mood disorders such as depression and bipolar disorder, particularly during pregnancy, postpartum and perimenopause. The report notes that postpartum depression affects 10-15 percent of women any time from a month to a year after childbirth and its cause remains unknown. Researchers suspect that the dramatic shifts in hormone levels during pregnancy and immediately afterward may result in chemical changes in the brain leading to postpartum depression. Similarly, perimenopause transitions in women may also increase risk of depression, and subsequently could lead to cardiovascular mortality.

"Science has revealed clues as to why these changes may occur in some women but further research is needed to definitively show what causes depression and mood disorders in women during hormonal transitions," said Schmidt. "The report outlines directions for further research, as recommended by myself and the roundtable participants."

According to the report, areas of research that need further exploration include:

-- Pregnancy: Research is needed to better distinguish symptoms of

depression from normal responses to the stressful experiences of

pregnancy.

-- Postpartum: Registries of collected reproductive safety information

on antidepressant, antipsychotic and anticonvulsant medications

must be created.

-- Perimenopause: Research is needed to uncover the susceptibility

markers that predict which women are at risk for developing

depression during perimenopause.

In addition to the report, the Society unveiled at the briefing a new national survey of physicians and consumers about their views regarding depression across hormonal transitions. The survey found that women underestimate depression risk at hormonal transitions throughout life. Additionally, women and doctors have widely divergent opinions on whether women can safely take medications for depression during pregnancy and in the postpartum period.

The full report, survey results and additional information about mood disorders and their relation to hormonal changes in women can be found at the Society's Web site, http://www.womenshealthresearch.org.

The thought leaders' roundtable was supported by the Marjorie Kovler Fund and the Jennifer Mudd Houghtaling Postpartum Depression Foundation.

The media briefing and satellite media tour were supported by Wyeth Pharmaceuticals, a division of Wyeth that has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, hemophilia, oncology and vaccines.

Drs. Schmidt and Marts will be available to answer additional questions and provide further information about hormonal fluctuations and their impact on depression during a satellite media tour on Wednesday, November 14. For more information about the satellite media tour, please contact Alyssa Sullivan at 212-599-1797 or via email at Sullivan@homefront.tv.

The Society for Women's Health Research is the nation's only not-for-profit organization whose mission is to improve the health of all women through research, education and advocacy. Founded in 1990, the Society brought to national attention the need for the appropriate inclusion of women in major medical research studies and the need for more information about conditions affecting women disproportionately, predominately, or differently than men. The Society advocates increased funding for research on women's health; encourages the study of sex differences that may affect the prevention, diagnosis and treatment of disease; promotes the inclusion of women in medical research studies; and informs women, providers, policy makers and media about contemporary women's health issues. Visit the Society's Web site at http://www.womenshealthresearch.org for more information.


'/>"/>
SOURCE Society for Women's Health Research
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arbios Announces Management Changes
2. Renovis Announces Management Changes
3. Bradmer announces management changes
4. Streamline Health Announces Executive Management Changes
5. Onyx Pharmaceuticals Announces Management Changes
6. How pitching changes little leaguers shoulders
7. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
8. Medicare Changes Didnt Alter Cancer Care
9. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
10. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
11. Imaging shows structural changes in mild traumatic brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... serving the families and businesses of the Norwalk and Vermillion areas, celebrates ... Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... owned and organized by HMP Communications Holdings, LLC, today announced that RestorixHealth® ... its nationwide network of wound centers interested in becoming Certified Wound Specialist Physicians ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... and workflow solutions, today named The Resource Group as their 2016 Microsoft Dynamics ... partner conference in Newport Beach, CA. The award recognizes The Resource Group ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... supplements that help improve all aspects of people’s health and nutrition, announced its ... nutritional products. , Natural Subsistence develops nutritional supplements that help people improve ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Leaders ... life-altering and fatal diseases in opposition to the President’s Fiscal Year 2018 ... care, services, and hope for the most vulnerable among us. , The proposed ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)...  The U.S. Food and Drug Administration today granted ... adults and pediatric patients 12 years and older with ... not received prior chemotherapy. This is the first FDA-approved ... skin cancer. "While skin cancer is one ... form called Merkel cell cancer have not had an ...
(Date:3/23/2017)... and VANCOUVER, British Columbia , ... SPHS ) (the "Company" or "Sophiris"), a clinical ... of urological diseases, today announced that data from its ... drug as a focal treatment for localized prostate cancer, ... 2017 at the 32 nd Annual European Association ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: